Everest Medicines, a biopharma company, announced that China's National Medical Products Administration has accepted their IND application for the drug candidate zetomipzomib in China.

FDA Grants Approval for CARsgen's Experimental Treatment CT071 for Use in Cases of Recurrent Multiple Myeloma and Primary Plasma Cell Leukemia After Prior Therapies Fail.

Brenig Therapeutics Reveals Enhanced Safety Metrics for its LRRK2 Blocker BT-0267 Featuring Notable CSF-to-Blood Concentration at the Parkinson's Disease Symposium.

The prominent science and technology corporation, Merck, has declared a formal licensing contract with the Shanghai-based firm Abbisko Therapeutics Co. Ltd.

Ascletis Pharma Inc. has declared the commencement of a pivotal Phase III clinical study for its fatty acid synthase inhibitor, ASC40 (Denifanstat) , aimed at addressing the therapeutic needs of individuals with moderate to severe acne vulgaris.

Merus N.V. has revealed fresh interim clinical findings on their candidate molecule MCLA-129.

UCB has received the green light from European regulators to market ZILBRYSQ[®] (zilucoplan) as a therapeutic option for generalized Myasthenia Gravis in adult patients.

Sana Biotechnology Releases Initial Clinical Findings Demonstrating SC291, an Off-the-Shelf CAR T Treatment Targeting CD19, Remains Undetected by a Functional Immune System.

Benitec Biopharma has reported initial dosing in an early-stage trial for its genetic treatment prospect, BB-301, aimed at tackling Oculopharyngeal Muscular Dystrophy.

Ambrx Reports Progress on APEX-01 Trial, a Phase 1 / 2 Study Assessing Increasing Doses of ARX517, Its Own PSMA-Directed Antibody-Drug Conjugate, in Advanced Prostate Cancer Unresponsive to Hormonal Therapy.

uniQure N.V., a leader in gene therapy, has announced FDA approval of its IND application for AMT-191 to treat severe medical conditions.

BioVie Inc., a biopharmaceutical firm focusing on neurological, neurodegenerative, and severe liver diseases, reported positive initial results from its Phase 3 trial of NE3107 in mild to moderate Alzheimer’s patients.